Jump to content

Pirenzepine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Monkbot (talk | contribs) at 03:22, 2 December 2020 (Task 18 (cosmetic): eval 4 templates: del empty params (1×);). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

"Tabe" redirects here. For the assessment tests called TABE, see Tests of Adult Basic Education.
Pirenzepine
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 11-[(4-methylpiperazin-1-yl)acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.044.739 Edit this at Wikidata
Chemical and physical data
FormulaC19H21N5O2
Molar mass351.410 g·mol−1
3D model (JSmol)
  • O=C3c1ccccc1N(C(=O)CN2CCN(C)CC2)c4ncccc4N3
  • InChI=1S/C19H21N5O2/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24/h2-8H,9-13H2,1H3,(H,21,26) checkY
  • Key:RMHMFHUVIITRHF-UHFFFAOYSA-N checkY
  (verify)

Pirenzepine (Gastrozepin), an M1 selective antagonist, is used in the treatment of peptic ulcers, as it reduces gastric acid secretion and reduces muscle spasm. It is in a class of drugs known as muscarinic receptor antagonists - acetylcholine being the neurotransmitter of the parasympathetic nervous system which initiates the rest-and-digest state (as opposed to fight-or-flight), resulting in an increase in gastric motility and digestion; whereas pirenzepine would inhibit these actions and cause decreased gastric motility leading to delayed gastric emptying and constipation.[1] It has no effects on the brain and spinal cord as it cannot diffuse through the blood–brain barrier.

Pirenzepine has been investigated for use in myopia control.[2][3]

It promotes the homodimerization or oligomerisation of M1 receptors.[4]

See also

References

  1. ^ Stolerman IP (2 August 2010). Encyclopedia of Psychopharmacology. Springer. p. 811. ISBN 978-3-540-68698-9. Retrieved 26 June 2013.
  2. ^ Czepita D (2005). "[Fundamentals of modern treatment of myopia]". Annales Academiae Medicae Stetinensis. 51 (2): 5–9. PMID 16519089.
  3. ^ Walline, Jeffrey J.; Lindsley, Kristina B.; Vedula, S. Swaroop; Cotter, Susan A.; Mutti, Donald O.; Ng, Sueko M.; Twelker, J. Daniel (13 January 2020). "Interventions to slow progression of myopia in children". The Cochrane Database of Systematic Reviews. 1: CD004916. doi:10.1002/14651858.CD004916.pub4. ISSN 1469-493X. PMC 6984636. PMID 31930781.
  4. ^ Pediani JD, Ward RJ, Godin AG, Marsango S, Milligan G (June 2016). "Dynamic Regulation of Quaternary Organization of the M1 Muscarinic Receptor by Subtype-selective Antagonist Drugs". The Journal of Biological Chemistry. 291 (25): 13132–46. doi:10.1074/jbc.M115.712562. PMC 4933229. PMID 27080256.{{cite journal}}: CS1 maint: unflagged free DOI (link)


Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Pirenzepine&oldid=991848743"